Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

PURPOSE: Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Choueiri, Toni K., Vaishampayan, Ulka, Rosenberg, Jonathan E., Logan, Theodore F., Harzstark, Andrea L., Bukowski, Ronald M., Rini, Brian I., Srinivas, Sandy, Stein, Mark N., Adams, Laurel M., Ottesen, Lone H., Laubscher, Kevin H., Sherman, Laurie, McDermott, David F., Haas, Naomi B., Flaherty, Keith T., Ross, Robert, Eisenberg, Peter, Meltzer, Paul S., Merino, Maria J., Bottaro, Donald P., Linehan, W. Marston, Srinivasan, Ramaprasad
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2013
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3532390/
https://ncbi.nlm.nih.gov/pubmed/23213094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.43.3383
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky